The John Charnley award: Heritable thrombophilia and development of thromboembolic disease after total hip arthroplasty

Clinical Orthopaedics and Related Research

Volumn 441, Issue , 2005, Pages 40-55

  Salvati, Eduardo A ^a,b   Della Valle, Alejandro González ^a   Westrich, Geoffrey H ^a   Rana, Adam J ^c   Specht, Lawrence ^d   Weksler, Babette B ^e   Wang, Ping ^f   Glueck, Charles J ^f  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c SUNY Downstate Medical Center   (United States)

^d LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^f JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANTITHROMBIN III DEFICIENCY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; FIBRINOLYSIS; GENE MUTATION; HUMAN; LUNG EMBOLISM; MALE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; SCREENING TEST; THROMBOEMBOLISM; THROMBOPHILIA; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM; ARTICLE; ECONOMICS; EMBOLISM; GENETICS; HEALTH CARE COST; HETEROZYGOTE; HIP ARTHROPLASTY; HOMOZYGOTE; HYPOPROTHROMBINEMIA; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTITHROMBIN III DEFICIENCY; ARTHROPLASTY, REPLACEMENT, HIP; EMBOLISM; FEMALE; HEALTH CARE COSTS; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPOPROTHROMBINEMIAS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROTEIN C DEFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 33644790098     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000192366.61616.81     Document Type: Conference Paper

References (148)

1. Alberts MJ: Genetics of cerebrovascular disease. Stroke 35:342-344, 2004.
2. Anderson Jr FA, Hirsh J, White K, et al: Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: Findings from the Hip and Knee Registry. Chest 124:349S-356S, 2003.
3. Anderson Jr FA, Wheeler HB: Natural history and epidemiology of venous thromboembolism. Orthop Rev 23:5-9, 1994.
4. Anderson Jr FA, Wheeler HB, Goldberg RJ, et al: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: The Worcester DVT Study. Arch Intern Med 151:933-938, 1991.
5. Bae H, Westrich GH, Sculco TP, et al: The effect of preoperative donation of autologous blood on deep-vein thrombosis after total hip arthroplasty. J Bone Joint Surg 83B:676-679, 2001.
6. Balasa VV, Gruppo RA, Glueck CJ, et al: The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults. Thromb Haemost 81:739-744, 1999.
7. Balasa VV, Gruppo RA, Glueck CJ, et al: Legg-Calve-Perthes disease and thrombophilia. J Bone Joint Surg 86A:2642-2647, 2004.
8. Barnes RW, Brand RA, Clarke W, et al: Efficacy of graded-compression antiembolism stockings in patients undergoing total hip arthroplasty. Clin Orthop Relat Res 132:61-67, 1978.
9. Berry DJ: Venous thromboembolism after a total hip arthroplasty: Prevention and treatment. Instr Course Lect 52:275-280, 2003.
10. Bertina RM: Molecular risk factors for thrombosis. Thromb Haemost 82:601-609, 1999.
11. Bertina RM: The prothrombin 20210 G to A variation and thrombosis. Curr Opin Hematol 5:339-342, 1998.
12. Bertina RM, Koeleman BP, Koster T, et al: Mutation in blood coagulation Factor V associated with resistance to activated protein C. Nature 369:64-67, 1994.
13. Bertina RM, Rosendaal FR: Venous thrombosis - The interaction of genes and environment. N Engl J Med 338:1840-1841, 1998.
14. Betrosian AP, Theodossiades G, Lambroulis G, et al: Heparin-induced thrombocytopenia with pulmonary embolism and disseminated intravascular coagulation associated with low-molecular-weight heparin. Am J Med Sci 325:45-47, 2003.
15. Binns M, Pho R: Femoral vein occlusion during hip arthroplasty. Clin Orthop Relat Res 255:168-172, 1990.
16. Bovill EG, Hasstedt SJ, Leppert MF, et al: Hereditary thrombophilia as a model for multigenic disease. Thromb Haemost 82:662-666, 1999.
17. Brenner B: Inherited thrombophilia and pregnancy loss. Thromb Haemost 82:634-640, 1999.
18. Broekmans AW, Veltkamp JJ, Bertina RM: Congenital protein C deficiency and venous thromboembolism: A study of three Dutch families. N Engl J Med 309:340-344, 1983.
19. Callaghan JJ, Dorr LD, Engh GA, et al: Prophylaxis for thromboembolic disease. J Arthroplasty 20:273-274, 2005.
20. Caprini JA, Botteman MF, Stephens JM, et al: Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 6:59-74, 2003.
21. Clark JA, Bremner BR: Fatal warfarin-induced skin necrosis after total hip arthroplasty. J Arthroplasty 17:1070-1073, 2002.
22. Collaborative overview: of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 308:81-106, 1994.
23. Collaborative overview: of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ 308:159-168, 1994.
24. Collaborative overview: of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. BMJ 308:235-246, 1994.
25. Crowther MA, Kelton JG: Congenital thrombophilic states associated with venous thrombosis: A qualitative overview and proposed classification system. Ann Intern Med 138:128-134, 2003.
26. Dahl OE, Gudmundsen TE, Bjornara BT, et al: Risk of clinical pulmonary embolism after joint surgery in patients receiving low-molecular-weight heparin prophylaxis in hospital: A 10-year prospective register of 3,954 patients. Acta Orthop Scand 74:299-304, 2003.
27. Dahlback B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a co-factor to activated protein C. Proc Natl Acad Sci USA 90:1004-1008, 1993.
28. De Stefano V, Zappacosta B, Persichilli S, et al: Prevalence of mild hyperhomocysteinaemia and association with thrombophilic genotypes (Factor V Leiden and prothrombin G20210A) in Italian patients with venous thromboembolic disease. Br J Haematol 106:564-568, 1999.
29. Della Valle CJ, Issack PS, Baitner A, et al: The relationship of the Factor V Leiden mutation or the deletion-deletion polymorphism of the angiotensin converting enzyme to postoperative thromboembolic events following total joint arthroplasty. BMC Musculoskelet Disord 2:1, 2001.
30. den Heijer M, Koster T, Blom HJ, et al: Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759-762, 1996.
31. DiGiovanni CW, Restrepo A, Gonzalez Della Valle AG, et al: The safety and efficacy of intraoperative heparin in total hip arthroplasty. Clin Orthop Relat Res 379:178-185, 2000.
32. Egeberg O: Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 13:516-530, 1965.
33. Engbersen AM, Franken DG, Boers GH, et al: Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 56:142-150, 1995.
34. Falcon CR, Cattaneo M, Panzeri D, et al: High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 14:1080-1083, 1994.
35. FDA Public Health Advisory: Reports of epidural or spinal hematomas with the concurrent use of low molecular weight heparin and spinal/epidural anesthesia or spinal puncture. U.S. Department of Health and Human Resources. Washington, DC, December 15, 1997.
36. Ferrari B, Baudouy M, Cerboni P: Clinical epidemiology of venous thromboembolic disease. Results of a French multicenter registry. Eur Heart J 18:681-691, 1997.
37. Final report: on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 321:129-135, 1989.
38. Franco RF, Reitsma PH: Genetic risk factors of venous thrombosis. Hum Genet 109:369-384, 2001.
39. Freedman KB, Brookenthal KR, Fitzgerald Jr RH, et al: A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg 82A:929-938, 2000.
40. Friedman RJ, Dunsworth GA: Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty. Clin Orthop Relat Res 370:171-182, 2000.
41. Frosst P, Blom HJ, Milos R, et al: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111-113, 1995.
42. Geerts WH, Pineo GF, Heit JA, et al: Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:338S-400S, 2004.
43. Gitel SN, Salvati EA, Wessler S, et al: The effect of total hip replacement and general surgery on antithrombin III in relation to venous thrombosis. J Bone Joint Surg 61A:653-656, 1979.
44. Glueck CJ, Bell H, Vadlamani L, et al: Heritable thrombophilia and hypofibrinolysis: Possible causes of retinal vein occlusion. Arch Ophthalmol 117:43-49, 1999.
45. Glueck CJ, Fontaine RN, Gruppo R, et al: The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop Relat Res 366:133-146, 1999.
46. Glueck CJ, Goldenberg N, Wang P, et al: Ramifications of four concurrent thrombophilic mutations and one hypofibrinolytic mutation. Clin Appl Thromb Hemost 10:365-371, 2004.
47. Glueck CJ, Kupferminc MJ, Fontaine RN, et al: Genetic hypofibrinolysis in complicated pregnancies. Obstet Gynecol 97:44-48, 2001.
48. Glueck CJ, Wang P, Goldenberg N, et al: Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin Appl Thromb Hemost 10:323-334, 2004.
49. Gonzalez Della Valle A, Ruzo PS, Salvati EA: Warfarin-associated intracapsular hemorrhage causing an acutely painful total hip arthroplasty: A rare complication of prolonged anticoagulant therapy. J Arthroplasty 15:668-670, 2000.
50. Griffin JH, Evatt B, Zimmerman TS, et al: Deficiency of protein C in congenital thrombotic disease. J Clin Invest 68:1370-1373, 1981.
51. Gum PA, Thamilarasan M, Watanabe J, et al: Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. JAMA 286:1187-1194, 2001.
52. Haas S: Deep vein thrombosis: beyond the operating table. Orthopedics 23:s629-s632, 2000.
53. Harrington RA, Becker RC, Ezekowitz M, et al: Antithrombotic therapy for coronary artery disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:513S-548S, 2004.
54. Heijboer H, Brandjes DP, Buller HR, et al: Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 323:1512-1516, 1990.
55. Holm J, Zoller B, Svensson PJ, et al: Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 344:952-953, 1994.
56. Hooker JA, Lachiewicz PF, Kelley SS: Efficacy of prophylaxis against thromboembolism with intermittent pneumatic compression after primary and revision total hip arthroplasty. J Bone Joint Surg 81A:690-696, 1999.
57. Humphries SE, Morgan L: Genetic risk factors for stroke and carotid atherosclerosis: Insights into pathophysiology from candidate gene approaches. Lancet Neurol 3:227-235, 2004.
58. Hundsdoerfer P, Vetter B, Stover B, et al: Homozygous and double heterozygous Factor V Leiden and Factor II G20210A genotypes predispose infants to thromboembolism but are not associated with an increase of foetal loss. Thromb Haemost 90:628-635, 2003.
59. Imperiale TF, Speroff T: A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 271:1780-1785, 1994.
60. Johnson R, Green JR, Charnley J: Pulmonary embolism and its prophylaxis following the Charnley total hip replacement. Clin Orthop Relat Res 127:123-132, 1977.
61. Jordan FL, Nandorff A: The familial tendency in thrombo-embolic disease. Acta Med Scand 156:267-275, 1956.
62. Kahn SR, Ginsberg JS: Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med 164:17-26, 2004.
63. Kahn SR, Hirsch A, Shrier I: Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med 162:1144-1148, 2002.
64. Kang SS, Zhou J, Wong PW, et al: Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 43:414-421, 1988.
65. Kim YH, Oh SH, Kim JS: Incidence and natural history of deep-vein thrombosis after total hip arthroplasty: A prospective and randomised clinical study. J Bone Joint Surg 85B:661-665, 2003.
66. Koster T, Rosendaal FR, Briet E, et al: Protein C deficiency in a controlled series of unselected outpatients: An infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 85:2756-2761, 1995.
67. Kottke-Marchant K, Duncan A: Antithrombin deficiency: Issues in laboratory diagnosis. Arch Pathol Lab Med 126:1326-1336, 2002.
68. Kupferminc MJ, Eldor A, Steinman N, et al: Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 340:9-13, 1999.
69. Lane DA, Grant PJ: Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 95:1517-1532, 2000.
70. Lawton RL, Morrey BF, Narr BJ: Validity of index of suspicion for pulmonary embolism after hip arthroplasty. Clin Orthop Relat Res 415:180-192, 2003.
71. Lensen R, Bertina RM, Vandenbroucke JP, et al: High factor VIII levels contribute to the thrombotic risk in families with Factor V Leiden. Br J Haematol 114:380-386, 2001.
72. Lie SA, Engesaeter LB, Havelin LI, et al: Early postoperative mortality after 67,548 total hip replacements: Causes of death and thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999. Acta Orthop Scand 73:392-399, 2002.
73. Lieberman JR: Venous thromboembolism after total hip arthroplasty. In Callaghan JJ, Rosenberg AG, Rubash HE (eds). The Adult Hip. Philadelphia, Lippincott-Raven 633-646, 1998.
74. Lotke PA, Palevsky H, Keenan AM, et al: Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop Relat Res 374:251-258, 1996.
75. Lowe GD, Haverkate F, Thompson SG, et al: Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: The ECAT DVT Study. European Concerted Action on Thrombosis. Thromb Haemost 81:879-886, 1999.
76. Macaulay W, Westrich G, Sharrock N, et al: Effect of pneumatic compression on fibrinolysis after total hip arthroplasty. Clin Orthop Relat Res 399:168-176, 2002.
77. Madonna P, de Stefano V, Coppola A, et al: Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke 33:51-56, 2002.
78. Makris M: Hyperhomocysteinemia and thrombosis. Clin Lab Haematol 22:133-143, 2000.
79. Mantilla CB, Horlocker TT, Schroeder DR, et al: Frequency of myocardial infarction, pulmonary embolism, deep venous thrombosis, and death following primary hip or knee arthroplasty. Anesthesiology 96:1140-1146, 2002.
80. Mantilla CB, Horlocker TT, Schroeder DR, et al: Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. Anesthesiology 99:552-560; Discussion 555A, 2003.
81. Martinelli I, De Stefano V, Taioli E, et al: Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 87:791-795, 2002.
82. Martinelli I, Mannucci PM, De Stefano V, et al: Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: A study of 150 families. Blood 92:2353-2358, 1998.
83. Martinelli I, Taioli E, Cetin I, et al: Recurrent late fetal death in women with and without thrombophilia. Thromb Haemost 87:358-359, 2002.
84. Mateo J, Oliver A, Borrell M, et al: Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism - Results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 77:444-451, 1997.
85. McCardel BR, Lachiewicz PF, Jones K: Aspirin prophylaxis and surveillance of pulmonary embolism and deep vein thrombosis in total hip arthroplasty. J Arthroplasty 5:181-185, 1990.
86. McNally MA, McAlinden MG, O'Connell BM, et al: Postphlebitic syndrome after hip arthroplasty: 43 patients followed at least 5 years. Acta Orthop Scand 65:595-598, 1994.
87. Mesko JW, Brand RA, Iorio R, et al: Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: A survey of the AAHKS membership. J Arthroplasty 16:679-688, 2001.
88. Miles JS, Miletich JP, Goldhaber SZ, et al: G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol 37:215-218, 2001.
89. Moll S: Warfarin-induced skin necrosis. Br J Haematol 126:628, 2004.
90. Mont MA, Jones LC, Rajadhyaksha AD, et al: Risk factors for pulmonary emboli after total hip or knee arthroplasty. Clin Orthop Relat Res 422:154-163, 2004.
91. Morita H, Taguchi J, Kurihara H, et al: Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 95:2032-2036, 1997.
92. Murin S, Marelich GP, Arroliga AC, et al: Hereditary thrombophilia and venous thromboembolism. Am J Respir Crit Care Med 158:1369-1373, 1998.
93. Murray DW, Britton AR, Bulstrode CJ: Thromboprophylaxis and death after total hip replacement. J Bone Joint Surg 78B:863-870, 1996.
94. Nizankowska-Mogilnicka E, Adamek L, Grzanka P, et al: Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis. Eur Respir J 21:25-30, 2003.
95. Pabinger I, Grafenhofer H, Kaider A, et al: Preeclampsia and fetal loss in women with a history of venous thromboembolism. Arterioscler Thromb Vasc Biol 21:874-879, 2001.
96. Pagnani MJ, Pellicci PM, Salvati EA: Effect of aspirin on heterotopic ossification after total hip arthroplasty in men who have osteoarthrosis. J Bone Joint Surg 73A:924-929, 1991.
97. Pezzini A, Del Zotto E, Archetti S, et al: Plasma homocysteine concentration, C677T MTHFR genotype, and 844ins68bp CBS genotype in young adults with spontaneous cervical artery dissection and atherothrombotic stroke. Stroke 33:664-669, 2002.
98. Philipp CS, Dilley A, Saidi P, et al: Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty. Thromb Haemost 80:869-873, 1998.
99. Phillips CB, Barrett JA, Losina E, et al: Incidence rates of dislocation, pulmonary embolism, and deep infection during the first six months after elective total hip replacement. J Bone Joint Surg 85A:20-26, 2003.
100. Planes A, Samama MM, Lensing AW, et al: Prevention of deep vein thrombosis after hip replacement - Comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost 81:22-25, 1999.
101. Planes A, Vochelle N, Fagola M: Total hip replacement and deep vein thrombosis: A venographic and necropsy study. J Bone Joint Surg 72B:9-13, 1990.
102. Poort SR, Rosendaal FR, Reitsma PH, et al: A common genetic variation in the 3́-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698-3703, 1996.
103. Prevention of: pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 355:1295-1302, 2000.
104. Prevention of: venous thrombosis and pulmonary embolism. NIH Consensus Development. JAMA 256:744-749, 1986.
105. Reitsma PH: Genetic heterogeneity in hereditary thrombophilia. Haemostasis 30:1-10, 2000.
106. Robertson KA, Bertot AJ, Wolfe MW, et al: Patient compliance and satisfaction with mechanical devices for preventing deep venous thrombosis after joint replacement. J South Orthop Assoc 9:182-186, 2000.
107. Rodeghiero F, Tosetto A: Activated protein C resistance and Factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 130:643-650, 1999.
108. Rosendaal FR: Risk factors for venous thrombotic disease. Thromb Haemost 82:610-619, 1999.
109. Rosendaal FR: Venous thrombosis: Prevalence and interaction of risk factors. Haemostasis 29(Suppl S1):1-9, 1999.
110. Rosendaal FR, Koster T, Vandenbroucke JP, et al: High risk of thrombosis in patients homozygous for Factor V Leiden (activated protein C resistance). Blood 85:1504-1508, 1995.
111. Ruiz-Quezada S, Vazquez-Del Mercado M, Parra-Rojas I, et al: Genotype and allele frequency of PAI-1 promoter polymorphism in healthy subjects from the west of Mexico: Association with biochemical and hematological parameters. Ann Genet 47:155-162, 2004.
112. Ryan DH, Crowther MA, Ginsberg JS, et al: Relation of Factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med 128:270-276, 1998.
113. Ryan MG, Westrich GH, Potter HG, et al: Effect of mechanical compression on the prevalence of proximal deep venous thrombosis as assessed by magnetic resonance venography. J Bone Joint Surg 84A:1998-2004, 2002.
114. Salvati EA, Gonzalez Della Valle A: Thromboembolism following total hip replacement. J Long Term Eff Med Implants 13:325-340, 2003.
115. Salvati EA, Pellegrini Jr VD, Sharrock NE, et al: Recent advances in venous thromboembolic prophylaxis during and after total hip replacement. J Bone Joint Surg 82A:252-270, 2000.
116. Sanchez-Ballester J, Smith M, Hassan K, et al: Wound infection in the management of hip fractures: A comparison between low-molecular weight heparin and mechanical prophylaxis. Acta Orthop Belg 71:55-59, 2005.
117. Sarmiento A, Goswami AD: Thromboembolic prophylaxis with use of aspirin, exercise, and graded elastic stockings or intermittent compression devices in patients managed with total hip arthroplasty. J Bone Joint Surg 81A:339-346, 1999.
118. Shaieb MD, Watson BN, Atkinson RE: Bleeding complications with enoxaparin for deep venous thrombosis prophylaxis. J Arthroplasty 14:432-438, 1999.
119. Sharrock NE, Go G, Harpel PC, et al: The John Charnley Award:Thrombogenesis during total hip arthroplasty. Clin Orthop Relat Res 319:16-27, 1995.
120. Sharrock NE, Go G, Sculco TP, et al: Dose response of intravenous heparin on markers of thrombosis during primary total hip replacement. Anesthesiology 90:981-987, 1999.
121. Sharrock NE, Salvati EA: Hypotensive epidural anesthesia for total hip arthroplasty: A review. Acta Orthop Scand 67:91-107, 1996.
122. Silbersack Y, Taute BM, Hein W, et al: Prevention of deep-vein thrombosis after total hip and knee replacement: Low-molecular-weight heparin in combination with intermittent pneumatic compression. J Bone Joint Surg 86B:809-812, 2004.
123. Simioni P, Prandoni P, Burlina A, et al: Hyperhomocysteinemia and deep-vein thrombosis. A case-control study. Thromb Haemost 76:883-886, 1996.
124. Srinivasan AF, Rice L, Bartholomew JR, et al: Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 164:66-70, 2004.
125. Sudo A, Sano T, Horikawa K, et al: The incidence of deep vein thrombosis after hip and knee arthroplasties in Japanese patients: A prospective study. J Orthop Surg (Hong Kong) 11:174-177, 2003.
126. Tait RC, Walker ID, Reitsma PH, et al: Prevalence of protein C deficiency in the healthy population. Thromb Haemost 73:87-93, 1995.
127. van Bockxmeer FM, Mamotte CD, Vasikaran SD, et al: Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 95:21-23, 1997.
128. Van Cott EM, Laposata M, Prins MH: Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Arch Pathol Lab Med 126:1281-1295, 2002.
129. van der Meer FJ, Koster T, Vandenbroucke JP, et al: The Leiden Thrombophilia Study (LETS). Thromb Haemost 78:631-635, 1997.
130. Wahlander K, Larson G, Lindahl TL, et al: Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. Thromb Haemost 87:580-585, 2002.
131. Warkentin TE: Heparin-induced thrombocytopenia. Curr Hematol Rep 1:63-72, 2002.
132. Warkentin TE, Kelton JG: Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135:502-506, 2001.
133. Warkentin TE, Kelton JG: Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344:1286-1292, 2001.
134. Warkentin TE, Levine MN, Hirsh J, et al: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330-1335, 1995.
135. Warwick D, Williams MH, Bannister GC: Death and thromboembolic disease after total hip replacement: A series of 1162 cases with no routine chemical prophylaxis. J Bone Joint Surg 77B:6-10, 1995.
136. Weisberg I, Tran P, Christensen B, et al: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169-172, 1998.
137. Weitz JI: New anticoagulants for treatment of venous thromboembolism. Circulation 110:I19-I26, 2004.
138. Westrich GH, Farrell C, Bono JV, et al: The incidence of venous thromboembolism after total hip arthroplasty: A specific hypotensive epidural anesthesia protocol. J Arthroplasty 14:456-463, 1999.
139. Westrich GH, Specht LM, Sharrock NE, et al: Pneumatic compression hemodynamics in total hip arthroplasty. Clin Orthop Relat Res 372:180-191, 2000.
140. Westrich GH, Weksler BB, Glueck CJ, et al: Correlation of thrombophilia and hypofibrinolysis with pulmonary embolism following total hip arthroplasty: An analysis of genetic factors. J Bone Joint Surg 84A:2161-2167, 2002.
141. White RH: The epidemiology of venous thromboembolism. Circulation 107:I4-I8, 2003.
142. White RH, Gettner S, Newman JM, et al: Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 343:1758-1764, 2000.
143. White RH, Zhou H, Romano PS: Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 90:446-455, 2003.
144. Woolson ST, McCrory DW, Walter JF, et al: B-mode ultrasound scanning in the detection of proximal venous thrombosis after total hip replacement. J Bone Joint Surg 72A:983-987, 1990.
145. Woolson ST, Robinson RK, Khan NQ, et al: Deep venous thrombosis prophylaxis for knee replacement: Warfarin and pneumatic compression. Am J Orthop 27:299-304, 1998.
146. Woolson ST, Zehnder JL, Maloney WJ: Factor V Leiden and the risk of proximal venous thrombosis after total hip arthroplasty. J Arthroplasty 13:207-210, 1998.
147. Zoller B, Garcia de Frutos P, Hillarp A, et al: Thrombophilia as a multigenic disease. Haematologica 84:59-70, 1999.
148. Zoller B, Svensson PJ, He X, et al: Identification of the same Factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 94:2521-2524, 1994.